Basic Research in Cardiology

, Volume 104, Issue 5, pp 465–467

Diastolic heart failure: a misNOmer

Clearly, there are many patients with obvious heart failure symptoms, more women than men and more often with heart failure of hypertensive than ischemic origin, who have surprisingly little impairment of left ventricular ejection fraction [4, 5, 19, 20]. The increasing awareness that a relatively preserved ejection fraction does not exclude heart failure has led some, including Westermann et al. [16] in this issue, to propose the concept of “diastolic heart failure”. Westermann et al. used the model of salt-induced hypertension in genetically susceptible rats with the subsequent development of left ventricular hypertrophy and ultimately heart failure and report the attenuation of the observed unfavorable alterations in left ventricular, notably diastolic function, morphology and signaling with concomitant pharmacological enhancement of endothelial nitric oxide (NO) synthase activity. The present opinionated editorial refutes the idea of “diastolic heart failure” as a genuine pathophysiological entity in its own standing and, accordingly, identifies the term “diastolic heart failure” as a misnomer. Why?
  1. 1.

    Heart failure is defined and its severity classified by clinical symptoms, i.e., dyspnea, edema, exercise intolerance, cachexia, etc. None of these symptoms can be attributed, not by the patient and not by his physician, to either systole or diastole.

  2. 2.

    Virtually, all studies on “diastolic heart failure” which looked at systolic ventricular function more carefully than just measuring ejection fraction, systolic ventricular function was in fact also impaired, notably in terms of regional left ventricular function and longitudinal ventricular shortening. Systolic left ventricular function impairment in “diastolic heart failure” is evident also in these authors’ clinical and experimental data. In their recent excellent clinical study [15], left ventricular end-diastolic pressure in patients with “diastolic heart failure” was 16.1 mmHg on the average and thus half of them missed the definition of “diastolic heart failure” according to the ESC consensus document, i.e., left ventricular end-diastolic pressure >16 mmHg [12]; nevertheless, these patients had reduced stroke volume and cardiac output which just missed statistical significance. Also, in their present experimental study [16] in rats with salt-induced hypertension and consequent heart failure, not only left ventricular diastolic function but again stroke volume and cardiac output were significantly reduced.

  3. 3.

    Morphological and molecular findings in “diastolic heart failure” are non-specific, i.e., reflect heart failure, its temporal progression, and its underlying origin. With respect to the present experimental study [16], hypertrophy and fibrosis are typical consequences of long-standing hypertension and by no means characteristic of “diastolic heart failure”; the same is true for the activation of MAP kinases [11] and calcineurin. Systolic and simultaneously diastolic impairment of calcium transients in human heart failure is well established [1]. Apart from the underlying origin of heart failure, the temporal progression of all observed molecular, morphological and functional phenomena has to be taken into serious consideration; in this respect, “diastolic heart failure” may just be a relatively early stage in the progression to more severe heart failure.

  4. 4.

    “Diastolic heart failure” is not suited as a new drug target. In the CHARM-preserved trial [18] in patients with heart failure and preserved left ventricular ejection fraction, candesartan was not better than placebo with respect to the primary endpoint of cardiovascular death and hospital admission for heart failure. Likewise, in the I-PRESERVE trial [10], irbesartan was not better than placebo with respect to the primary endpoint of death from any cause and hospitalization for a cardiovascular cause. In the Hong Kong diastolic heart failure study [17], diuretics improved heart failure symptoms significantly, and neither irbesartan nor ramipiril provided additional benefit. Finally, in the ALLHAT trial, antihypertensive therapy with thiazide diuretics reduced the incidence of new onset heart failure with preserved ejection fraction more than lisinopril [3, 9]. Collectively, these studies reflect only modest activation of neurohumoral systems, and they are consistent with a relatively early stage of heart failure.


A beneficial effect of NO at low concentration on both systolic [14] and diastolic [13] left ventricular function in humans is well established, as is a dysbalance of NO in heart failure [2, 6]. Importantly, the origin of NO matters for myocardial function: NO derived from endothelial NO synthase optimizes contractile function for a given myocardial oxygen consumption [8]; whereas, NO derived from inducible NO synthase contributes to contractile dysfunction in experimental short-term hibernating myocardium [7]. For the present experimental study [16], however, it is entirely unclear to what extent the pharmacological enhancement of endothelial NO synthase attenuated the development of hypertension through a vascular action or had any independent effect on systolic and/or diastolic function of the failing heart. There is an obvious and understandable commercial interest of the pharmaceutical industry to create a new disease and in consequence identify a new target for their particular product. Again, “diastolic heart failure” is no new drug target.


  1. 1.
    Beuckelmann DJ, Näbauer M, Erdmann E (1992) Intracellular calcium handling in isolated ventricular myocytes from patients with terminal heart failure. Circulation 85:1046–1055PubMedGoogle Scholar
  2. 2.
    Cotton JM, Kearney MT, Shah AM (2002) Nitric oxide and myocardial function in heart failure: friend or foe? Heart 88:564–566PubMedCrossRefGoogle Scholar
  3. 3.
    Davis BR, Kostis JB, Simpson LM, Black HR, Cushman WC, Einhorn PT, Farber MA, Ford CE, Levy D, Massie BM, Nawaz S (2008) Heart failure with preserved and reduced left ventricular ejection fraction in the antihypertensive and lipid-lowering treatment to prevent heart attack Trial. Circulation 118:2259–2267PubMedCrossRefGoogle Scholar
  4. 4.
    De Keulenaer GW, Brutsaert DL (2007) Diastolic heart failure: a separate disease or selection bias? Prog Cardiovasc Dis 49:275–283PubMedCrossRefGoogle Scholar
  5. 5.
    Dickstein K, Cohen-Solal A, Filippatos G, McMurray JJ, Ponikowski P, Poole-Wilson PA, Stromberg A, van Veldhuisen DJ, Atar D, Hoes AW, Keren A, Mebazaa A, Nieminen M, Priori SG, Swedberg K, Vahanian A, Camm J, De CR, Dean V, Dickstein K, Filippatos G, Funck-Brentano C, Hellemans I, Kristensen SD, McGregor K, Sechtem U, Silber S, Tendera M, Widimsky P, Zamorano JL, Tendera M, Auricchio A, Bax J, Bohm M, Corra U, Della BP, Elliott PM, Follath F, Gheorghiade M, Hasin Y, Hernborg A, Jaarsma T, Komajda M, Kornowski R, Piepoli M, Prendergast B, Tavazzi L, Vachiery JL, Verheugt FW, Zamorano JL, Zannad F (2008) ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2008: the task force for the diagnosis and treatment of acute and chronic heart failure 2008 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association of the ESC (HFA) and endorsed by the European Society of Intensive Care Medicine (ESICM). Eur Heart J 29:2388–2442PubMedCrossRefGoogle Scholar
  6. 6.
    Hare JM, Stamler JS (2005) NO/redox disequilibrium in the failing heart and cardiovascular system. J Clin Invest 115:509–517PubMedGoogle Scholar
  7. 7.
    Heinzel FR, Gres P, Boengler K, Duschin A, Konietzka I, Rassaf T, Snedovskaya J, Meyer S, Skyschally A, Kelm M, Heusch G, Schulz R (2008) Inducible nitric oxide synthase expression and cardiomyocyte dysfunction during sustained moderate ischemia in pigs. Circ Res 103:1120–1127PubMedCrossRefGoogle Scholar
  8. 8.
    Heusch G, Post H, Michel MC, Kelm M, Schulz R (2000) Endogenous nitric oxide and myocardial adaptation to ischemia. Circ Res 87:146–152PubMedGoogle Scholar
  9. 9.
    Little WC (2008) Hypertension, heart failure, and ejection fraction. Circulation 118:2223–2224PubMedCrossRefGoogle Scholar
  10. 10.
    Massie BM, Carson PE, McMurray JJ, Komajda M, McKelvie R, Zile MR, Anderson S, Donovan M, Iverson E, Staiger C, Ptaszynska A (2008) Irbesartan in patients with heart failure and preserved ejection fraction. N Engl J Med 359:2456–2467PubMedCrossRefGoogle Scholar
  11. 11.
    Michel MC, Li Y, Heusch G (2001) Mitogen-activated protein kinases in the heart. Naunyn-Schmiedeberg’s Arch Pharmacol 363:245–266CrossRefGoogle Scholar
  12. 12.
    Paulus WJ, Tschope C, Sanderson JE, Rusconi C, Flachskampf FA, Rademakers FE, Marino P, Smiseth OA, De KG, Leite-Moreira AF, Borbely A, Edes I, Handoko ML, Heymans S, Pezzali N, Pieske B, Dickstein K, Fraser AG, Brutsaert DL (2007) How to diagnose diastolic heart failure: a consensus statement on the diagnosis of heart failure with normal left ventricular ejection fraction by the Heart Failure and Echocardiography Associations of the European Society of Cardiology. Eur Heart J 28:2539–2550PubMedCrossRefGoogle Scholar
  13. 13.
    Paulus WJ, Vantrimpont PJ, Shah AM (1994) Acute effects of nitric oxide on left ventricular relaxation and diastolic distensibility in humans. Assessment by biocoronary sodium nitroprusside infusion. Circulation 89:2070–2078PubMedGoogle Scholar
  14. 14.
    Rassaf T, Poll LW, Brouzos P, Lauer T, Totzeck M, Kleinbongard P, Gharini P, Andersen K, Schulz R, Heusch G, Mödder U, Kelm M (2006) Positive effects of nitric oxide on left ventricular function in humans. Eur Heart J 27:1699–1705PubMedCrossRefGoogle Scholar
  15. 15.
    Westermann D, Kasner M, Steendijk P, Spillmann F, Riad A, Weitmann K, Hoffmann W, Poller W, Pauschinger M, Schultheiss HP, Tschope C (2008) Role of left ventricular stiffness in heart failure with normal ejection fraction. Circulation 117:2051–2060PubMedCrossRefGoogle Scholar
  16. 16.
    Westermann D, Riad A, Richter U, Jäger S, Bergmann N, Gotthardt M, Nagorsen D, Schultheiss H-P, Tschöpe C (2009) Enhancement of the endothelial NO synthase attenuates experimental diastolic heart failure. Basic Res Cardiol. doi:10.1007/s00395-009-0014-6
  17. 17.
    Yip GW, Wang M, Wang T, Chan S, Fung JW, Yeung L, Yip T, Lau ST, Lau CP, Tang MO, Yu CM, Sanderson JE (2008) The Hong Kong diastolic heart failure study: a randomised controlled trial of diuretics, irbesartan and ramipril on quality of life, exercise capacity, left ventricular global and regional function in heart failure with a normal ejection fraction. Heart 94:573–580PubMedCrossRefGoogle Scholar
  18. 18.
    Yusuf S, Pfeffer MA, Swedberg K, Granger CB, Held P, McMurray JJV, Michelson EL, Olofsson B, Östergren J (2003) Effects of candesartan in patients with chronic heart failure and preserved left-ventricular ejection fraction: the CHARM-preserved trial. Lancet 362:777–781PubMedCrossRefGoogle Scholar
  19. 19.
    Zile MR, Brutsaert DL (2002) New concepts in diastolic dysfunction and diastolic heart failure: part I. Diagnosis, prognosis, and measurements of diastolic function. Circulation 105:1387–1393PubMedCrossRefGoogle Scholar
  20. 20.
    Zile MR, Brutsaert DL (2002) New concepts in diastolic dysfunction and diastolic heart failure: Part II. Causal mechanisms and treatment. Circulation 105:1503–1508PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag 2009

Authors and Affiliations

  1. 1.Direktor des Instituts für PathophysiologieUniversitätsklinikum EssenEssenGermany

Personalised recommendations